Purdue Pharma has agreed to pay $225 million to the U.S. Justice Department. The payment resolves a yearslong criminal case against the pharmaceutical company.
The company faced allegations of fueling the opioid crisis. Federal prosecutors accused Purdue of misleading doctors and patients about the risks of its painkiller OxyContin.
The settlement marks a significant conclusion to the legal battle. It does not admit or deny wrongdoing as part of the agreement.
The Justice Department claimed Purdue prioritized profits over public safety. The company’s marketing practices were central to the case.
The opioid epidemic has caused hundreds of thousands of deaths nationwide. Purdue’s role in the crisis has been under scrutiny for decades.
The payment will be directed to federal programs addressing addiction and drug misuse. Officials stated the funds aim to support treatment and prevention efforts.
Purdue previously filed for bankruptcy as part of a broader restructuring. The company continues to face lawsuits from states and individuals.
The case represents a key moment in holding pharmaceutical companies accountable. Critics argue the settlement amount is insufficient given the scale of the crisis.
